Home > Result Summaries: Compounds > fosamprenavir > Result Summary for 100732

Result Summary for 100732

Result Summary

Protocol ID:	100732
Clinical Study ID:	APV100732
Official Title:	See Detailed Description
Phase:	phase 3
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	fosamprenavir
Trade/Product Name:	Telzir,Telzer,Lexiva
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Pulido F, Estrada V, Baril JG, et al. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. [HIV Clin Trials]. 2009;10(2):76-87. Eron JJ, Yeni P, Gathe JC, et al. The KLEAN Study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir/lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet, 2006. 368: 476-82.